AVE 33.3% 0.2¢ avecho biotechnology limited

financial misappropriation ann is out, page-137

  1. 1,539 Posts.
    Trader Paul.

    Re : A search for Ogru’s replacement is under way; until then Rosen will be the interim chief executive. He will no doubt be reflecting on the merits of appointing Ogru in the first place, and whether the “joint CEO” role, with him based in New York, was best for the company.

    "Once bitten twice shy" - Harry had better screen and qualify future candidates with real business qualifications,not scientific, real business experience and learn from his past poor reflection on promoting from within - too many large stakeholders given plum roles in POH IMHO and that's a fact!
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.